| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on May 22, 2003; DOI 10.1182/blood-2002-11-3444.
Blood, 15 September 2003, Vol. 102, No. 6, pp. 1997-2003 Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7![]() From the VU University Medical Center Amsterdam, The Netherlands; Department of Pathology, University of Erlangen, Germany; Childhood Cancer Research Group, Oxford, United Kingdom; IRCCS Policlinico S. Matteo, Pavia, Italy; Skejby Hospital, University of Aarhus, Denmark; Department of Pediatrics, University of British Columbia, Vancouver, Canada; Department of Pediatrics, Second Medical Faculty, Charles University, Prague, Czech Republic; Department of Pediatrics and Pathology, University of Freiburg, Germany; Department of Pediatrics, University of Giessen, Germany; Department of Haematology and Oncology, Great Ormond Street Children's Hospital, London, United Kingdom; Cattedra di Ematologia, University La Sapienza of Roma, Italy; Laboratory Department, Istituti Clinici di Perfezionamento, Milan, Italy; Department of Pathology, University of Odense, Denmark; and the Dutch Children Leukemia Study Group, The Hague, The Netherlands.
Primary myelodysplasia (MDS) without an increased number of blasts is a rare finding in childhood. We performed a retrospective analysis of 67 children with a diagnosis of primary MDS to determine the clinical and hematologic course of the disease. The median age at diagnosis was 8.3 years (range, 0.3-18.1 years). In contrast to refractory anemia in adults, 44% of patients had hemoglobin levels greater than 10 g/100 mL. The median white blood cell count and the absolute neutrophil count were 3.6 x 109/L and 0.9 x 109/L, respectively. Seventy-five percent of patients had thrombocytopenia. Bone marrow was hypocellular in 43% of the patients. Results of cytogenetic analysis showed monosomy 7 in 49%, trisomy 8 in 9%, and other abnormalities in 9% of the patients. The probability of survival 10 years after diagnosis was 0.48 (standard error [SE] = 0.10). Patients with monosomy 7 had significantly higher estimated probabilities of progression to advanced MDS than did patients with other chromosomal anomalies or normal karyotype. Of the 67 children, 41 underwent allogeneic stem cell transplantation (SCT). Patients whose disease did not progress to advanced MDS before SCT had significantly greater probability of survival than patients who experienced progression (0.76 [SE = 0.09] vs 0.36 [SE = 0.16]). SCT improved the outcomes for patients with monosomy 7 and should be offered early in the course of the disease. Recommendations for best treatment options for children with other chromosomal abnormalities or normal karyotype may have to await results of prospective clinical trials.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||